Lummy(SZ:300006)2023-04-21 16:00Revenue and Financial Performance - Revenue for the first quarter of 2023 increased by 14.06% to 226,654,528.42 yuan compared to the same period last year[2] - Total revenue for the quarter was 226.65 million yuan, an increase from 198.71 million yuan in the same period last year[20] - Sales revenue from goods and services was 220.995 million USD, a decrease from 259.388 million USD in the previous year[24] Net Profit and Loss - Net loss attributable to shareholders of the listed company decreased to -3,634,060.91 yuan from -26,403,512.18 yuan year-over-year[2] - Net profit for the first quarter of 2023 was -7.606 million USD, a significant improvement from -28.991 million USD in the same period last year[21] Cash Flow - Operating cash flow turned positive at 9,591,286.80 yuan, compared to -12,698,605.55 yuan in the same period last year[2] - Net cash flow from operating activities was 903.78 million yuan, compared to 846.29 million yuan at the beginning of the year[16] - Operating cash flow for the first quarter of 2023 was 9.591 million USD, compared to -12.699 million USD in the same period last year[25] - Investment cash flow improved significantly, with a net inflow of 38,635,590.92 yuan compared to a net outflow of 81,194,088.89 yuan last year[11] - Investment cash flow for the first quarter of 2023 was 38.636 million USD, a significant improvement from -81.194 million USD in the same period last year[25] - Financing cash flow for the first quarter of 2023 was 9.701 million USD, compared to 138.912 million USD in the same period last year[25] - Cash and cash equivalents at the end of the first quarter of 2023 were 852.320 million USD, an increase from 794.829 million USD at the beginning of the quarter[25] Assets and Liabilities - Total assets increased by 0.94% to 3,083,794,077.47 yuan compared to the end of the previous year[2] - The company's total assets increased to 3.08 billion yuan, up from 3.05 billion yuan at the beginning of the year[18] - Total liabilities increased to 902.18 million yuan, up from 870.02 million yuan at the beginning of the year[18] - The company's total equity decreased slightly to 2.18 billion yuan, down from 2.18 billion yuan at the beginning of the year[18] - The company's inventory decreased to 192.77 million yuan, down from 202.40 million yuan at the beginning of the year[17] - The company's accounts receivable increased to 359.72 million yuan, up from 331.45 million yuan at the beginning of the year[17] - The company's long-term loans decreased to 133.00 million yuan, down from 149.00 million yuan at the beginning of the year[18] R&D and Expenses - R&D expenses decreased by 34.81% to 15,677,120.11 yuan due to different stages of R&D projects[9] - R&D expenses for the first quarter of 2023 were 15.677 million USD, a decrease from 24.047 million USD in the same period last year[21] - Sales expenses for the first quarter of 2023 were 125.912 million USD, an increase from 113.151 million USD in the same period last year[21] - Management expenses for the first quarter of 2023 were 28.511 million USD, a decrease from 29.479 million USD in the same period last year[21] Financial Expenses and Income - Financial expenses showed a significant improvement, with a net income of 2,981,316.04 yuan compared to an expense of 1,858.23 yuan last year[9] Government Subsidies - The company received government subsidies of 10,930,854.65 yuan during the reporting period[4] Shareholders and Ownership - The number of ordinary shareholders at the end of the reporting period was 34,995[12] - Guangxi Wuzhou Zhongheng Group Co., Ltd. holds 23.43% of the company's shares, making it the largest shareholder[12] Product and Regulatory Approvals - The company's product, Tranexamic Acid Injection, was selected in the 8th National Drug Centralized Procurement[14] - The company received approval from the National Medical Products Administration for the transfer of the drug approval of Triptorelin Acetate Injection[14] Audit Status - The company's first quarter report for 2023 was not audited[26]